Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sickle Cell Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H2 2016, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 8, 9, 1, 24, 7 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively for Sickle Cell Disease. Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders). - The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Sickle Cell Disease Overview 6 Therapeutics Development 7 Sickle Cell Disease - Therapeutics under Development by Companies 9 Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes 13 Sickle Cell Disease - Pipeline Products Glance 14 Sickle Cell Disease - Products under Development by Companies 18 Sickle Cell Disease - Products under Investigation by Universities/Institutes 21 Sickle Cell Disease - Companies Involved in Therapeutics Development 22 Sickle Cell Disease - Therapeutics Assessment 56 Drug Profiles 68 Sickle Cell Disease - Dormant Projects 176 Sickle Cell Disease - Discontinued Products 179 Sickle Cell Disease - Product Development Milestones 180 Appendix 191
List of Tables
Number of Products under Development for Sickle Cell Disease, H2 2016 14 Number of Products under Development for Sickle Cell Disease - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Comparative Analysis by Unknown Stage Development, H2 2016 24 Products under Development by Companies, H2 2016 25 Products under Development by Companies, H2 2016 (Contd..1) 26 Products under Development by Companies, H2 2016 (Contd..2) 27 Products under Investigation by Universities/Institutes, H2 2016 28 Sickle Cell Disease - Pipeline by Acceleron Pharma, Inc., H2 2016 29 Sickle Cell Disease - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 30 Sickle Cell Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 31 Sickle Cell Disease - Pipeline by Advinus Therapeutics Ltd, H2 2016 32 Sickle Cell Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 33 Sickle Cell Disease - Pipeline by Angiocrine Bioscience, Inc., H2 2016 34 Sickle Cell Disease - Pipeline by Bio Products Laboratory Ltd, H2 2016 35 Sickle Cell Disease - Pipeline by bluebird bio, Inc., H2 2016 36 Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Company, H2 2016 37 Sickle Cell Disease - Pipeline by Complexa, Inc., H2 2016 38 Sickle Cell Disease - Pipeline by CRISPR Therapeutics, H2 2016 39 Sickle Cell Disease - Pipeline by CSL Limited, H2 2016 40 Sickle Cell Disease - Pipeline by Editas Medicine, Inc., H2 2016 41 Sickle Cell Disease - Pipeline by Emmaus Medical, Inc., H2 2016 42 Sickle Cell Disease - Pipeline by Errant Gene Therapeutics, LLC, H2 2016 43 Sickle Cell Disease - Pipeline by Gamida Cell Ltd., H2 2016 44 Sickle Cell Disease - Pipeline by Gilead Sciences, Inc., H2 2016 45 Sickle Cell Disease - Pipeline by Global Blood Therapeutics, Inc., H2 2016 46 Sickle Cell Disease - Pipeline by Johnson & Johnson, H2 2016 47 Sickle Cell Disease - Pipeline by La Jolla Pharmaceutical Company, H2 2016 48 Sickle Cell Disease - Pipeline by Merck & Co., Inc., H2 2016 49 Sickle Cell Disease - Pipeline by Modus Therapeutics Holding AB, H2 2016 50 Sickle Cell Disease - Pipeline by Morphogenesis, Inc., H2 2016 51 Sickle Cell Disease - Pipeline by NKT Therapeutics, Inc., H2 2016 52 Sickle Cell Disease - Pipeline by Novartis AG, H2 2016 53 Sickle Cell Disease - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 54 Sickle Cell Disease - Pipeline by Pfizer Inc., H2 2016 55 Sickle Cell Disease - Pipeline by PharmaEssentia Corporation, H2 2016 56 Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 57 Sickle Cell Disease - Pipeline by Protagonist Therapeutics Inc., H2 2016 58 Sickle Cell Disease - Pipeline by ReveraGen BioPharma, Inc., H2 2016 59 Cell Disease - Pipeline by Sancilio & Company, Inc., H2 2016 60 Sickle Cell Disease - Pipeline by Sangamo BioSciences, Inc., H2 2016 61 Sickle Cell Disease - Pipeline by Selexys Pharmaceuticals Corporation, H2 2016 62 Assessment by Monotherapy Products, H2 2016 63 Assessment by Combination Products, H2 2016 64 Number of Products by Stage and Target, H2 2016 66 Number of Products by Stage and Mechanism of Action, H2 2016 69 Number of Products by Stage and Route of Administration, H2 2016 72 Number of Products by Stage and Molecule Type, H2 2016 74 Sickle Cell Disease - Dormant Projects, H2 2016 183 Sickle Cell Disease - Dormant Projects (Contd..1), H2 2016 184 Sickle Cell Disease - Dormant Projects (Contd..2), H2 2016 185 Sickle Cell Disease - Discontinued Products, H2 2016 186
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
